Byungjoo Kim, CEO of SoluM Healthcare (left), Kwunho Jeong, CEO of JNPMEDI (right)
Medical data platform company JNPMEDI, led by CEO Kwunho Jeong, announced on the 1st that it has signed a Memorandum of Understanding (MOU) with SoluM Healthcare, a subsidiary of SoluM (CEO Sungho Jeon), led by CEO Byungjoo Kim, to develop and commercialize a sensor-based rapid cancer diagnostic solution.
JNPMEDI, which provides the clinical trial solution 'Maven Clinical Cloud,' will collaborate with SoluM Healthcare, which holds key technology for diagnosing major cancers using urine samples, to push forward clinical trials and medical device regulatory approval projects under this MOU.
JNPMEDI will focus on enhancing the algorithms needed for the rapid cancer diagnostic solution and shortening the regulatory approval process. Utilizing its expertise in medical device regulatory approval, clinical consulting, and its 'Maven Clinical Cloud' solution, JNPMEDI aims to eliminate bottlenecks in the preparation and execution of clinical trials.
SoluM Healthcare plans to prepare for mass production of strip-type diagnostic kits using urine samples, establish a lab for global project execution, and strengthen its healthcare network. The combined strengths of SoluM Healthcare's global network and its parent company's manufacturing capabilities could position it as a game-changer in the cancer diagnostics market.
CEO Kwunho Jeong of JNPMEDI stated, "By combining SoluM Healthcare's core technology with JNPMEDI's IT capabilities and clinical strategy expertise, we aim to create a successful case of commercializing early cancer diagnosis technology. We will not only act as a clinical trial partner but also walk strategically with SoluM Healthcare to help it become a world-leading bio-healthcare company."
CEO Byungjoo Kim of SoluM Healthcare commented, "JNPMEDI's extensive experience in clinical trials and regulatory approval will expedite the commercialization of SoluM's early cancer diagnosis solution. We are establishing a dedicated research site for this project and will diligently follow the regulatory procedures to contribute to the widespread adoption of early cancer diagnosis."
Byungjoo Kim, CEO of SoluM Healthcare (left), Kwunho Jeong, CEO of JNPMEDI (right)
Medical data platform company JNPMEDI, led by CEO Kwunho Jeong, announced on the 1st that it has signed a Memorandum of Understanding (MOU) with SoluM Healthcare, a subsidiary of SoluM (CEO Sungho Jeon), led by CEO Byungjoo Kim, to develop and commercialize a sensor-based rapid cancer diagnostic solution.
JNPMEDI, which provides the clinical trial solution 'Maven Clinical Cloud,' will collaborate with SoluM Healthcare, which holds key technology for diagnosing major cancers using urine samples, to push forward clinical trials and medical device regulatory approval projects under this MOU.
JNPMEDI will focus on enhancing the algorithms needed for the rapid cancer diagnostic solution and shortening the regulatory approval process. Utilizing its expertise in medical device regulatory approval, clinical consulting, and its 'Maven Clinical Cloud' solution, JNPMEDI aims to eliminate bottlenecks in the preparation and execution of clinical trials.
SoluM Healthcare plans to prepare for mass production of strip-type diagnostic kits using urine samples, establish a lab for global project execution, and strengthen its healthcare network. The combined strengths of SoluM Healthcare's global network and its parent company's manufacturing capabilities could position it as a game-changer in the cancer diagnostics market.
CEO Kwunho Jeong of JNPMEDI stated, "By combining SoluM Healthcare's core technology with JNPMEDI's IT capabilities and clinical strategy expertise, we aim to create a successful case of commercializing early cancer diagnosis technology. We will not only act as a clinical trial partner but also walk strategically with SoluM Healthcare to help it become a world-leading bio-healthcare company."
CEO Byungjoo Kim of SoluM Healthcare commented, "JNPMEDI's extensive experience in clinical trials and regulatory approval will expedite the commercialization of SoluM's early cancer diagnosis solution. We are establishing a dedicated research site for this project and will diligently follow the regulatory procedures to contribute to the widespread adoption of early cancer diagnosis."